CXCR2: a target for pancreatic cancer treatment?

Author： Hertzer Kathleen M   Donald Graham W   Hines O Joe  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.6, 2013-09, pp. : 667-680

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TRAIL a target rather than a treatment?

By  

Inpharma, Vol. 1, Iss. 1254, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Is it worth increasing dose-density in cancer treatment?

By  

Inpharma, Vol. 1, Iss. 1246, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Resectable Non-Small Cell Lung Cancer in the Elderly: Is There a Role for Adjuvant Treatment?

By Langer Corey J.  

Drugs & Aging, Vol. 25, Iss. 3, 2008-01 ,pp. : 209-218

Adis International

Access to resources Recommend Favorite

Halofuginone for liver fibrosis prevention and treatment?

By  

Inpharma, Vol. 1, Iss. 1279, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Does alosetron have a place in IBS treatment?

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite